| DNA methylation in thyroid cancer C Zafon, J Gil, B Pérez-González, M Jordà Endocrine-related cancer 26 (7), R415-R439, 2019 | 94 | 2019 |
| Molecular profiling for acromegaly treatment: a validation study M Puig-Domingo, J Gil, M Sampedro-Nuñez, M Jordà, SM Webb, G Serra, ... Endocrine-Related Cancer 27 (6), 375-389, 2020 | 51 | 2020 |
| Pasireotide in the personalized treatment of acromegaly M Puig-Domingo, I Bernabéu, A Picó, B Biagetti, J Gil, C Alvarez-Escolá, ... Frontiers in Endocrinology 12, 648411, 2021 | 30 | 2021 |
| Lipid metabolism and epigenetics crosstalk in prostate cancer JC Pardo, V Ruiz de Porras, J Gil, A Font, M Puig-Domingo, M Jordà Nutrients 14 (4), 851, 2022 | 22 | 2022 |
| ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression S Hernández-Llodrà, N Juanpere, S de Muga, M Lorenzo, J Gil, ... Oncotarget 8 (43), 74106, 2017 | 22 | 2017 |
| Epithelial–mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly J Gil, M Jorda, B Soldevila, M Puig-Domingo Frontiers in Endocrinology 12, 646210, 2021 | 17 | 2021 |
| Data mining analyses for precision medicine in acromegaly: a proof of concept J Gil, M Marques-Pamies, M Sampedro, SM Webb, G Serra, I Salinas, ... Scientific Reports 12 (1), 8979, 2022 | 14 | 2022 |
| Implications of heterogeneity of epithelial-mesenchymal states in acromegaly therapeutic pharmacologic response J Gil, M Marques-Pamies, E Valassi, A García-Martínez, G Serra, ... Biomedicines 10 (2), 460, 2022 | 9 | 2022 |
| Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH‐producing adenomas J Gil, M Marques‐Pamies, M Jordà, C Fajardo‐Montañana, ... Clinical Endocrinology 94 (5), 811-819, 2021 | 9 | 2021 |
| Why don’t corticotroph tumors always produce Cushing’s disease? A García-Martínez, DA Cano, A Flores-Martínez, J Gil, M Puig-Domingo, ... European Journal of Endocrinology 181 (3), 351-361, 2019 | 8 | 2019 |
| Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly S Ruiz, J Gil, B Biagetti, E Venegas, R Cámara, R Garcia‐Centeno, ... Clinical Endocrinology 99 (4), 378-385, 2023 | 3 | 2023 |
| Molecular profiling for assistance to pharmacological treatment of acromegaly M Puig-Domingo, J Gil, M Sampedro, SM Webb, G Serra, I Salinas, ... Endocrine Abstracts 56, 2018 | 3 | 2018 |
| Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in Non-Functioning Pituitary Neuroendocrine Tumors J Gil, M Marques-Pamies, E Valassi, G Serra, I Salinas, G Xifra, ... Frontiers in Endocrinology 14, 594, 2023 | 2 | 2023 |
| Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly M Marques-Pamies, J Gil, E Valassi, M Hernández, B Biagetti, ... Frontiers in Endocrinology 14, 1269787, 2023 | 1 | 2023 |
| Pasireotide imaging study: magnetic resonance imaging as a predictor of therapeutic response in acromegaly S Ruiz, ME Venegas, J Gil, R CAMARA, B Biagetti, GMM Angeles, ... Endocrine Abstracts 81, 2022 | | 2022 |
| Characterization of epithelial-mesenchymal transition in growth hormone-secreting adenomas J Gil, M Marques-Pamies, A García-Martínez, G Serra, S Webb, ... Endocrine Abstracts 70, 2020 | | 2020 |
| Data mining analyses for precision medicine in acromegaly M Marques-Pamies, J Gil, M Jorda, SNM Antonio, S Webb, G Serra, ... Endocrine Abstracts 70, 2020 | | 2020 |
| Molecular profiling of non-functioning pituitary adenomas does not support pharmacological therapeutic options J Gil, A Blanco, G Serra, I Salinas, SM Webb, C Hostalot, G Obiols, ... Endocrine Abstracts 56, 2018 | | 2018 |
